Opthea Limited has completed the final week 52 patient visit in COAST and ShORe, two phase III pivotal trials that evaluated the efficacy and safety of sozinibercept in combination with other medications for the treatment of wet age-related macular degeneration (AMD). The topline results from both trials are expected in early and mid-CY25. With the FDA's Fast Track Designation, Opthea's phase III program aims to support approval for the use of sozinibercept in combination with any anti-VEGF-A therapy in wet AMD patients.

Source: Ophthalmology Management